FDA Office of Neuroscience argues for approval; non-binding recommendation from the Peripheral and Central Nervous System Drugs Advisory Committee is negative
TORONTO and CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today commented on the November 6th FDA Peripheral and Central Nervous System Drugs Advisory Committee meeting and its review of Biogens Biologics License Application (BLA) for aducanumab for the treatment of Alzheimers disease.
The key BLA components reviewed at the advisory committee meeting consisted of three clinical trials: two pivotal phase 3 trials of similar design (Study 301, 302) and one phase 1b trial (Study 103). Both Biogen and FDA acknowledged Study 301 (ENGAGE) was negative and could not contribute to the evidence for aducanumabs effectiveness. Demonstration of effectiveness for licensing generally requires two adequate and well-controlled clinical trials that are positive. However, under certain circumstances and consistent with the 1997 FDA Modernization Act, FDA can conclude that one adequate and well-controlled clinical investigation plus confirmatory evidence is sufficient to establish effectiveness. Whether Study 302 (EMERGE) provided adequate evidence as a single study a position strongly expressed by the FDA Office of Neuroscience represented the key issue debated by the Advisory Committee.
Dr. Billy Dunn, Director of the Office of Neuroscience, who convened the Advisory Committee and ultimately has the authority to approve the BLA, gave the FDA presentation; he summarized the Study 302 results, stating they were compelling, exceptionally persuasive, and represented a homerun. However, the written review by Dr. Tristan Massie, Office of Biostatistics, embedded in the FDA briefing documents for the Advisory Committee, addressed some Study 302 inconsistencies and argued against a conclusion of substantial evidence because of the conflicting results of the two phase 3 studies. FDA and Biogen conducted a number of subgroup analyses to explore why Study 301 and Study 302 were divergent in their results, but none of them provided a definitive answer and the committee members decided it was not possible to conclude aducanumab was effective for the treatment of Alzheimers disease.
Story continues
Thus, on the first and most critical question to the committee, Does Study 302, viewed independently and without regard for Study 301, provide strong evidence that supports effectiveness of aducanumab for the treatment of Alzheimers disease?, the committee vote was negative, with 1 Yes, 8 No and 2 Uncertain. To a large degree, the other three questions assumed a Yes vote to the first question, including the last question as to whether Study 302 could be considered as primary evidence of effectiveness.
It is important to note that, prior to and during the advisory committee meeting, the FDA Office of Neuroscience made several key arguments supporting approval of aducanumab, as outlined below:
Analysis of the data supporting the March 2019 decision to discontinue the trials because of futility did not provide an accurate reflection of individual studies. The futility decision was based on pooled data from both Study 301 and Study 302. However, if the two studies had been independently reviewed for futility, Study 302 would not have met the futility criteria and the magnitude of effect in the high-dose arm (10mg/kg) in fact improved over time as additional data were collected. FDA commented that it would have been more appropriate if futility had not been declared and noted that assumptions supporting the futility analysis had been violated.
In response to Biogens argument that anti-amyloid beta (A) antibodies differ considerably with respect to their molecular characteristics, FDA agreed that anti-A therapies do not represent a single class of drugs and previous late-stage failures of such therapies do not constitute a demonstrated class failure. During committee discussion, this point was briefly noted as members acknowledged that a more nuanced discussion of oligomers as the most toxic molecular A species was beyond the scope of the committees responsibility.
Although FDA will most likely accept the non-binding recommendations of the advisory committee, it is disappointing for patients, their caregivers and the research community that the committee viewed the inconsistencies in data as too significant to reach a conclusion that aducanumab is clinically effective, said Dr. James Kupiec, Chief Medical Officer for ProMIS Neurosciences. We are however encouraged by FDAs position on anti-A antibodies. The amyloid hypothesis is far from dead now that the research community is focused on the most toxic molecular species, and we anticipate that PMN310, which selectively targets toxic A oligomers, could demonstrate best-in-class effectiveness and safety in clinical studies.
After the Advisory Committee meeting, Mr. Michael Vounatsos, Chief Executive Officer at Biogen, expressed his gratitude for the patients and advocates who spoke at the meeting and reflected on the significant unmet need for a treatment for Alzheimers disease. Biogen noted they will continue to work with FDA as it completes its review of the BLA.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimers, ALS and Parkinsons disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins. In the infectious disease setting, these DSEs represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19. ProMIS proprietary peptide antigens can also be used to create potential therapeutic antibodies, as well as serve as the basis for development of vaccines. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
Visit us at http://www.promisneurosciences.com, follow us on Twitter and LinkedIn. To learn more about protein misfolding diseases, listen to Episodes 11, 24, of Saving Minds, a podcast available at iTunes or Spotify.
For media inquiries, please contact:
Shanti Skiffington shanti.skiffington@gmail.comTel. 617 921-0808
For Investor Relations please contact: Alpine Equity Advisors Nicholas Rigopulos, Presidentnick@alpineequityadv.comTel. 617 901-0785
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Read this article:
ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimers disease - Yahoo Finance
- 5 Brain Strategies to Dramatically Reduce Conflict and Boost Your Leadership, Backed by Neuroscience - Inc. - September 23rd, 2024 [September 23rd, 2024]
- Fascinating neuroscience research reveals a key mechanism underlying human cognition - PsyPost - September 23rd, 2024 [September 23rd, 2024]
- Averaging is a convenient fiction of neuroscience - The Transmitter: Neuroscience News and Perspectives - September 23rd, 2024 [September 23rd, 2024]
- Repeat scans reveal brain changes that precede childbirth - The Transmitter: Neuroscience News and Perspectives - September 23rd, 2024 [September 23rd, 2024]
- Neuroscience helps explain the teenage brain and mental health - ABC News - September 15th, 2024 [September 15th, 2024]
- XX Marks the Spot: Addressing Sex Bias in Neuroscience - The Scientist - September 15th, 2024 [September 15th, 2024]
- Neuroscience-based tools for transformative leadership - Fast Company - September 15th, 2024 [September 15th, 2024]
- How 100 Years of EEG Have Transformed Neuroscience - Being Patient - September 15th, 2024 [September 15th, 2024]
- Reconstructing dopamines link to reward - The Transmitter: Neuroscience News and Perspectives - September 15th, 2024 [September 15th, 2024]
- The neuroscience of itch in relation to transdiagnostic psychological approaches - Nature.com - September 15th, 2024 [September 15th, 2024]
- A README for open neuroscience - The Transmitter: Neuroscience News and Perspectives - September 15th, 2024 [September 15th, 2024]
- Dopamine and the need for alternative theories - The Transmitter: Neuroscience News and Perspectives - September 15th, 2024 [September 15th, 2024]
- Kim Stachenfeld on the dance between neuroscience and artificial intelligence - The Transmitter: Neuroscience News and Perspectives - September 15th, 2024 [September 15th, 2024]
- Vijay Mohan K. Namboodiri - The Transmitter: Neuroscience News and Perspectives - September 15th, 2024 [September 15th, 2024]
- Varied Cognitive Training Boosts Learning and Memory - Neuroscience News - September 15th, 2024 [September 15th, 2024]
- Issue | September 2024 | XX Marks the Spot: Addressing Sex Bias in Neuroscience - The Scientist - September 15th, 2024 [September 15th, 2024]
- The Transmitter Partners With World Wide Neuro and Brain Inspired, Building on Mission to Inform, Connect Neuroscience Community - StreetInsider.com - September 15th, 2024 [September 15th, 2024]
- Gene Therapy Offers Hope for Glaucoma and AMD - Neuroscience News - September 15th, 2024 [September 15th, 2024]
- The Neuroscience of Phantom Sensations: Can We Feel Whats Not Really There? - SciTechDaily - September 2nd, 2024 [September 2nd, 2024]
- Tau May Protect Brain Cells from Oxidative Damage - Neuroscience News - September 2nd, 2024 [September 2nd, 2024]
- Scientists use fainting to uncover new insights into the neuroscience of consciousness - PsyPost - September 2nd, 2024 [September 2nd, 2024]
- Biosensors and being fearless with Lin Tian - The Transmitter: Neuroscience News and Perspectives - September 2nd, 2024 [September 2nd, 2024]
- Can Neuroscience Train Your Brain to Be Happier? This Startup Has an App for That - Inc. - September 2nd, 2024 [September 2nd, 2024]
- Neuroscience Surprise: Different Types of Love Light Up Different Parts of the Brain - SciTechDaily - September 2nd, 2024 [September 2nd, 2024]
- Second paper from lab of Nobel Prize winner to be retracted - The Transmitter: Neuroscience News and Perspectives - September 2nd, 2024 [September 2nd, 2024]
- How cognitive bias affects your draft strategy with neuroscience professor Dr. Renee Miller - Yahoo Sports - August 5th, 2024 [August 5th, 2024]
- This 3-step approach to performance reviews uses neuroscience to make them less awful - Fast Company - August 5th, 2024 [August 5th, 2024]
- Is it time to worry about brain chimeras? - The Transmitter: Neuroscience News and Perspectives - August 5th, 2024 [August 5th, 2024]
- Sharing brain images can foster new neuroscience discoveries - American Heart Association - July 26th, 2024 [July 26th, 2024]
- Latest News: Neuroscience Major Applies What Shes Learned in the Classroom and in the Lab - Muhlenberg College - July 26th, 2024 [July 26th, 2024]
- BioIVT to Highlight its Integral Role in Drug and Diagnostic Discovery and Development in addition to Neuroscience Research at Premier Life Science... - July 26th, 2024 [July 26th, 2024]
- Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision... - July 26th, 2024 [July 26th, 2024]
- Neuroscience Says 3 Simple Steps Can Turn Disappointment and Stress Into Success and Fulfillment (and Boost Your Emotional Intelligence) - Inc. - July 26th, 2024 [July 26th, 2024]
- Golf: neuroscience reveals the secrets of better putting new study - The Conversation - July 26th, 2024 [July 26th, 2024]
- The Neuroscience Behind Video: Why Video is the Most Effective Marketing Channel - StreamTV Insider - July 26th, 2024 [July 26th, 2024]
- Building an autism research registry: Q&A with Tony Charman - The Transmitter: Neuroscience News and Perspectives - July 26th, 2024 [July 26th, 2024]
- Adjusting Proteins Increases Ozempics Effectiveness - Neuroscience News - July 18th, 2024 [July 18th, 2024]
- Low-Calorie Diets Harm Athletes Performance and Health - Neuroscience News - July 18th, 2024 [July 18th, 2024]
- Reflective Thinking Boosts Teen Brain Resilience to Violence - Neuroscience News - July 18th, 2024 [July 18th, 2024]
- Neuroscience Says Olympians Like Simone Biles Use the Autopilot Trick to Achieve Peak Performance. So Can You - Inc. - July 18th, 2024 [July 18th, 2024]
- What well-being is (and isnt), according to neuroscience - Big Think - July 18th, 2024 [July 18th, 2024]
- Brain Areas Take Micro-Naps While the Rest Stays Awake - Neuroscience News - July 18th, 2024 [July 18th, 2024]
- Persistent protein pairing enables memories to last - The Transmitter: Neuroscience News and Perspectives - July 18th, 2024 [July 18th, 2024]
- AI Enhances Story Creativity but Risks Reducing Novelty - Neuroscience News - July 18th, 2024 [July 18th, 2024]
- Infection Brain Inflammation Triggers Muscle Weakness - Neuroscience News - July 18th, 2024 [July 18th, 2024]
- Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of Buy from Analysts - Defense World - July 18th, 2024 [July 18th, 2024]
- 2024 Kavli Prize awarded for research on face-selective brain areas - The Transmitter: Neuroscience News and Perspectives - June 18th, 2024 [June 18th, 2024]
- Unlocking Flow: The Neuroscience of Creative Bliss - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Revolutionizing Glioblastoma Treatment - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Decoding spontaneous thoughts from the brain via machine learning - EurekAlert - April 15th, 2024 [April 15th, 2024]
- Reducing Toxic AI Responses - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Advancing the neuroscience of human pregnancy - Nature.com - April 15th, 2024 [April 15th, 2024]
- Angela Bryan Awarded Hazel Barnes Prize | Psychology and Neuroscience - University of Colorado Boulder - April 15th, 2024 [April 15th, 2024]
- How Old Are You in Your Head? The Neuroscience of Subjective Age Reveals How to Stay Mentally Young - Inc. - April 15th, 2024 [April 15th, 2024]
- Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of ... - PR Newswire - April 15th, 2024 [April 15th, 2024]
- Those Who Use Willpower Deemed More Trustworthy - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- How Sex and Gender Shape Our Cognition - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- War's Toll on the Brain: Widespread PTSD and Anxiety Among Ukrainians - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Paints and Pesticides Linked to ALS Risk - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- AI STORIES: A New Vision for AI and Narratives - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Neuroscience Breakthrough Unveils How We Learn and Remember - SciTechDaily - April 15th, 2024 [April 15th, 2024]
- Pregnancy's Toll: Accelerated Aging in Young Mothers - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Learning and Memory Formation's Molecular Basis - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Acetaminophen in Pregnancy Not Linked to Autism, ADHD Risk - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Childhood Loneliness Linked to Later Psychosis - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Vigil Neuroscience, Inc. (NASDAQ:VIGL) Expected to Post Q1 2024 Earnings of ($0.58) Per Share - Defense World - March 29th, 2024 [March 29th, 2024]
- International Brain Research Organisation (IBRO) Diversity Grants 2024 Opportunity Desk - Opportunity Desk - March 29th, 2024 [March 29th, 2024]
- Hereditary Alzheimer's Transmitted Via Bone Marrow Transplants - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Household Chemicals Linked to Brain Health Risks - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Cheers to Longevity: Couples Who Drink Together, Live Longer - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Sleeplessness Makes You Feel Up To Ten Years Older - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Aging Brain Cells Have Prolonged Death Process - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Anxiety Drives Wishful Thinking to Risky Levels - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Prolonged Progestogen Use Linked to Brain Tumor Risk - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- The Genetic Secrets of Neuron Formation - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Yahoo Finance - March 29th, 2024 [March 29th, 2024]
- Big research, little time: Medical neuroscience student wins 3 Minute Thesis finals - Dal News - March 29th, 2024 [March 29th, 2024]
- The new NeuroAI - Nature.com - March 29th, 2024 [March 29th, 2024]
- Exploring Aphantasia: The Mind Without a Mental Picture - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Altered Brain pH Linked to Cognitive Disorders - Neuroscience News - March 29th, 2024 [March 29th, 2024]